These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Selegiline, fluoxetine, and depression in Parkinson's disease. Garcia-Monco JC; Padierna A; Gomez Beldarrain M Mov Disord; 1995 May; 10(3):352. PubMed ID: 7651457 [No Abstract] [Full Text] [Related]
3. Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Montastruc JL; Chamontin B; Senard JM; Tran MA; Rascol O; Llau ME; Rascol A Lancet; 1993 Feb; 341(8844):555. PubMed ID: 8094789 [No Abstract] [Full Text] [Related]
4. Fluoxetine and selegiline--lack of significant interaction. Waters CH Can J Neurol Sci; 1994 Aug; 21(3):259-61. PubMed ID: 8000982 [TBL] [Abstract][Full Text] [Related]
5. Possible interactions between deprenyl and prozac. Suchowersky O; deVries J Can J Neurol Sci; 1990 Aug; 17(3):352-3. PubMed ID: 2119870 [No Abstract] [Full Text] [Related]
6. Interaction of fluoxetine and selegiline. Suchowersky O; deVries JD Can J Psychiatry; 1990 Aug; 35(6):571-2. PubMed ID: 2119876 [No Abstract] [Full Text] [Related]
7. Severe adverse interaction between pethidine and selegiline. Zornberg GL; Bodkin JA; Cohen BM Lancet; 1991 Jan; 337(8735):246. PubMed ID: 1670882 [No Abstract] [Full Text] [Related]
8. Transdermal selegiline (Emsam). Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292 [No Abstract] [Full Text] [Related]
9. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease]. Dubois B; Montastruc JL Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616 [No Abstract] [Full Text] [Related]
10. Interaction of fluoxetine and pentazocine. Hansen TE; Dieter K; Keepers GA Am J Psychiatry; 1990 Jul; 147(7):949-50. PubMed ID: 2356884 [No Abstract] [Full Text] [Related]
11. [Pseudopheochromocytoma in a parkinsonian patient treated with selegiline]. Messer-Kremer M; Herrscher M; Schlienger JL; Sagez JF Rev Med Interne; 1995; 16(3):229-30. PubMed ID: 7740240 [No Abstract] [Full Text] [Related]
13. Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. Ondo WG; Hunter C; Isaacson SH; Silver DE; Stewart RM; Tetrud JW; Davidson A Parkinsonism Relat Disord; 2011 Feb; 17(2):117-8. PubMed ID: 21084213 [TBL] [Abstract][Full Text] [Related]
14. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Ben-Shlomo Y; Lees A; Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425 [No Abstract] [Full Text] [Related]
15. [Selegiline in the therapy of Parkinson's disease]. Stojiljković MP; Dragojević-Simić V; Bosković B Vojnosanit Pregl; 1992; 49(4):357-68. PubMed ID: 1481452 [No Abstract] [Full Text] [Related]
16. Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects. Prescrire Int; 2003 Oct; 12(67):179. PubMed ID: 14619897 [TBL] [Abstract][Full Text] [Related]
18. Protective effect of selegiline in the early and late phases of Parkinson's disease. Csanda E; Tárczy M Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208 [No Abstract] [Full Text] [Related]
19. Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic. Preskorn SH J Psychiatr Pract; 2008 Jan; 14(1):45-54. PubMed ID: 18212602 [No Abstract] [Full Text] [Related]
20. Rasagiline as a therapy for Parkinson's disease (PD). Hermanowicz N Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520 [No Abstract] [Full Text] [Related] [Next] [New Search]